Celltrion Healthcare Launches Remsima® Monitor Kit in Europe
- Providing customized medical services for patients with autoimmune diseases by measuring serum drug concentration and anti-drug antibody production
- 20~30% of the cost of existing therapeutic drug monitoring methods … Distinguishing Remsima® by taking patient satisfaction into consideration
[April 3rd, 2017] Celltrion Healthcare, global marketing affiliate of Celltrion Inc., launched the Remsima® monitor kits in Europe on April 1st, 2017. The Remsima® monitor kits measure serum drug concentration and anti-drug antibody production for the optimization of biologic therapies in patients with autoimmune diseases.
The Remsima® monitor kits are therapeutic drug monitoring tools that measure drug concentration remaining in the serum and assess anti-drug antibody status in patients with autoimmune diseases treated with Remsima®. Based on the results of the tools, efficacy of treatment is expected to improve by adjusting time points of administration and dosage according to the patient's condition.
Celltrion Healthcare plans to provide the Remsima® monitor kits at an affordable price to increase accessibility and to provide customized medical services to patients by reducing the financial burden. Therefore, it is expected that the efficacy and satisfaction of patients administered with Remsima® will improve as the use of Remsima® monitor kits increase, and that it will contribute to the marketing activity distinguishing Remsima® from other TNF-α inhibitors (treatment of autoimmune disease) by providing high quality medical services.
Dr. Hyuk-Chan Kwon M.D., Ph.D., Head of Medical Affairs Department at Celltrion Healthcare, stated “the Remsima® monitor kits are launched as part of an effort to improve the quality and satisfaction of medical services by providing tailored treatment opportunities to individual patient,” followed by “the Remsima® monitor kits will also help to reduce medical costs, ultimately contributing to an improved share of Remsima®.”
Celltrion Healthcare is expecting to see a rapid increase of patients switching from reference infliximab to Remsima® by presenting scientific evidence for optimal treatment of each patient identified through real world prescription data of Remsima® and the monitor kits, maximizing market share by expanding marketing activities to the entire TNF-α inhibitor (treatment of autoimmune disease) market.